Filing excerpt
The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones.
Source: Autobound Signal API · 117 signals tracked for Bristol Myers Squibb · updated
Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API
What changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.Bristol Myers Squibb received FDA approval on September 30, 2026, for Camzyos to treat pediatric and adult obstructive hypertrophic cardiomyopathy, alongside regulatory approval of Zenbexus for multiple myeloma.
Filing excerpt
The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-8kproductLaunchGet every 8-K signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/e256edc1-0efc-4561-ab07-90b6800757f1 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.
{
"signal_id": "e256edc1-0efc-4561-ab07-90b6800757f1",
"signal_type": "sec-8k",
"signal_subtype": "productLaunch",
"detected_at": "2026-11-03T07:05:06.403+00:00",
"company": {
"name": "Bristol Myers Squibb",
"domain": "bms.com"
},
"data": {
"detail": "Bristol Myers Squibb received FDA approval on September 30, 2026, for Camzyos to treat pediatric and adult obstructive hypertrophic cardiomyopathy, alongside regulatory approval of Zenbexus for multiple myeloma. This rollout may create opportunities for commercialization vendors, specialized distribution partners, and digital healthcare engagement platforms.",
"metrics": {
"timeframe": "current_quarter"
},
"summary": "FDA Approves Camzyos for Obstructive Hypertrophic Cardiomyopathy and Zenbexus Brings First-in-Class Multiple Myeloma Treatment",
"excerpts": "The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones.",
"relevance": 0.85,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000022/bmy-20261029.htm",
"filing_date": "2026-10-29",
"filing_year": 2026,
"fiscal_year_end": "10/29",
"sales_relevance": "Go-to-market support",
"signal_category": "strategic",
"regions_mentioned": [
"U.S."
]
}
}
curl https://signals.autobound.ai/v1/signals/e256edc1-0efc-4561-ab07-90b6800757f1 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bms.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.